

Sisram Medical Group expects to record significant increases of more than 73% in its revenue and more than 190% in its profits for the First 6 Months of 2021, as compared to that for the corresponding period in 2020.

HONG KONG, July 5th, 2021 – Sisram Medical Ltd (“Sisram” or “the Company”) (Hong Kong: 1696), an operational holding company specializing in medical aesthetics technology for wellness, today announced that, based on the preliminary assessment of the unaudited consolidated management accounts of the Company for the six months ended June 30, 2021 (the “Period”) and the information currently available to the Board, the Group is expected to record significant increases of more than 73% in its revenue for the Period and more than 190% in its profits for the Period, in each case, as compared to that for the corresponding period in 2020.

The expected significant increases in revenue and profits for the Period are mainly attributable to the Group’s (i) global operation spanning across over 90 countries and regions worldwide, which facilitated the agility and mitigation of markets dynamics, (ii) strong position in its two leading markets: North America and China, (iii) resilience strategy, focused on retaining talents and company resources during the pandemic, (iv) strong synergistic collaboration between diverse product lines and distribution channels in the global medical aesthetics market, and (v) strong research and development capabilities, evidenced by the introduction of new technologies and the upgrade of existing ones.

The Board reminds Shareholders and potential investors that the information contained in this press release has not been reviewed or audited by the independent auditor or the audit committee of the Company and may subject to adjustment. The actual results of the Company for the Period may differ from the information contained in this press release. Detailed financial information of the Company for the Period will be disclosed in the interim results announcement of the Company for the Period, which is expected to be published before the end of August 2021.

###

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is one of the top 5 global leaders in the energy-based medical aesthetics industry. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board. Sisram Medical’s core subsidiary, Alma, is a global leading provider of energy-based surgical and medical aesthetics solutions and is active across over 90 countries and jurisdictions worldwide. Flagship systems of Sisram Medical include (i) the “Soprano” family, primarily used for laser hair removal; (ii) the “Harmony” family, a versatile multi-application platform that can be used to treat more than 65 different FDA-cleared indications; (iii) the “Accent” family, primarily used for body



Sisram Med (1696.HK)
復銳醫療科技 (1696.HK)

contouring and skin tightening; (iv) “FemiLift”, a minimally invasive treatment system for various feminine conditions; and (v) “BeautiFill” by LipoFlow platform, the first and only energy-based device cleared by the FDA for autologous fat grafting. In addition, Sisram Medical also entered the injectables market, with products available in Israel, Hong Kong and India.

Sisram Medical –Enhancing Quality of Life.

<http://www.sisram-medical.com>

For media inquiries, please contact:

ICR Inc.

Sijia Qian

Tel: +86 134-3670-4113

E-mail: Sijia.Qian@icrinc.com